5HT2 receptor changes in rat cortex and platelets following chronic ritanserin and clorgyline administration.
Chronic administration of clorgyline or ritanserin to adult rats for 28 days followed by a 3 day drug-free period results in a significant decrease in 5HT2 receptor number (Bmax) in rat frontal cortex from 315.23 +/- 10.72 fmol/mg protein to 249.63 +/- 13.99 fmol/mg protein and 222.55 +/- 17.17 fmol/mg protein, respectively. On rat blood platelets, ritanserin significantly increases recept number from 26.18 +/- 3.83 fmol/mg protein to 50.94 +/- 7.96 fmol bound/mg protein, whereas clorgyline has no significant effect (21.32 +/- 4.78 fmol/mg protein). Following both drug regimens, the affinity (Kd) of the respective ligands for the receptor is not significantly different from controls: the mean Kd value of the three groups for [3H]ketanserin is 1.57 +/- 0.05 nM in cortex and 0.83 +/- 0.25 nM for [125I]iodolysergic acid diethylamide (LSD) on platelets. Clorgyline increases serotonin (5HT) and noradrenaline (NA) levels in cerebellum, and decreases 5-hydroxyindole acetic acid (5HIAA) and homovanillic acid (HVA): ritanserin does not change the levels of the amines or their metabolites. The data shows that platelet and brain changes are not comparable after ritanserin administration. The receptor binding data demonstrates that curve fitting to two data points provides information which is comparable to and as statistically robust as that obtained from eight point saturation curves. Thus, if pilot studies show that the data follows a rectangular hyperbola, two point assays (optimal at 0.1 Kd and 3 Kd) can be used to obtain estimates of Bmax and Kd.
Twist
E C
EC
Department of Neuroscience, Institute of Psychiatry, De Crespigny Park, London, U.K.
Mitchell
S
S
Brazell
C
C
Stahl
S M
SM
Campbell
I C
IC
D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism*; D003010:Clorgyline / Q000008:administration & dosage / Q000494:pharmacology*; D006719:Homovanillic Acid / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D007650:Ketanserin / Q000378:metabolism; D008238:Lysergic Acid Diethylamide / Q000378:metabolism; D008297:Male; D009638:Norepinephrine / Q000378:metabolism; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology*; D011437:Propylamines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011985:Receptors, Serotonin / Q000378:metabolism*; D016713:Ritanserin; D012701:Serotonin / Q000378:metabolism
D010880:Piperidines; D011437:Propylamines; D011985:Receptors, Serotonin; D016713:Ritanserin; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D008238:Lysergic Acid Diethylamide; D007650:Ketanserin; D003010:Clorgyline; D009638:Norepinephrine; D006719:Homovanillic Acid